Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma
A phase 2 trial of durvalumab, tremelimumab and bevacizumab in gallbladder cancer and other biliary tract cancers, run by National Cancer Institute (NCI), active and no longer recruiting.
Overview
Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma is a phase 2 interventional study registered as NCT03937830 by National Cancer Institute (NCI), with a registry enrolment figure of 27 participants, started 2021-03-10 and due to reach its primary completion in 2026-12-31. Interventions recorded: durvalumab, Doxorubicin-Eluting Beads, TACE, bevacizumab, Tremelimumab. Conditions listed: Hepatocellular Cancer, Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma. Sites: United States. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialDurvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
Shares Tremelimumab, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab, Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
- TrialImmunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)
Shares Tremelimumab, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab, Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
- TrialEvaluating Novel Therapies in ctDNA Positive GI Cancers
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Bevacizumab, Biliary tract cancer (all types), Monoclonal antibodies and the tag gallbladder-deep-dive.
- TrialDurvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
Shares Tremelimumab, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab, Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
- TrialTrastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Monoclonal antibodies, Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
- TrialAgnostic Therapy in Rare Solid Tumors
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer and the tag gallbladder-deep-dive.
- TrialChemotherapy Combined With Adebrelimab and Mecapegfilgrastim in Neoadjuvant Treatment of Potentially Resectable BTC
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer and the tag gallbladder-deep-dive.
- TrialA Study of HRS-4642 Monotherapy or in Combination With Adebrelimab in the Treatment of Advanced Biliary Tract Tumors.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer and the tag gallbladder-deep-dive.